Somebody types “retatrutide dosage” at eleven at night, finds a table copied out of a clinical trial protocol, and reads it as a prescription. It was never a prescription. Retatrutide has no approved dose for the same reason it has no approved label, which is that no regulator has approved the drug.<\/p>\n
The one-sentence answer, before the evidence: the trial doses ran from 1 mg to 12 mg once weekly, stepped upward on a four-week schedule, and that schedule is a research protocol supervised by Eli Lilly, not a prescription any pharmacy can lawfully fill. The part that does transfer is that the speed of the climb changed the side effects more than the height of the target did.<\/p>\n
The agency’s page on unapproved GLP-1 drugs, checked on October 11, 2026, carries one sentence that ends the compounded conversation: “Retatrutide and cagrilintide cannot be used in compounding under federal law.” The same page adds that neither molecule sits inside an FDA-approved drug, and that the agency has not established either as safe and effective for any condition.<\/p>\n
Lilly runs blunter than the regulator. In the TRIUMPH-1 release of May 21, 2026<\/a>, the company writes that retatrutide “is an investigational molecule that is legally available only to participants in Lilly’s clinical trials.” Read that line as a dosage answer. A milligram figure printed on a vial sold online is not a prescription for an approved medicine, because there is no approved medicine to prescribe.<\/p>\n The FDA’s own dosing-error record makes the point. On the same page the agency describes “multiple reports of adverse events, some requiring hospitalization, that may be related to dosing errors associated with compounded injectable semaglutide products,” where patients measured the wrong amount and clinicians miscalculated. Those injuries happened with drugs that carry a label to measure against. Compounded products are not FDA-approved, and this molecule cannot be compounded at all.<\/p>\n TRIUMPH-1 randomized 2,339 adults with obesity and without diabetes in a 1:1:1:1 ratio to 4 mg, 9 mg or 12 mg of retatrutide, or placebo, once weekly for 80 weeks. Nobody opened at a target dose. Lilly’s release states the protocol in the company’s own words: “Participants randomized to retatrutide initiated treatment with 2 mg once weekly and increased the dose in a step-wise approach every four weeks until reaching the target dose of 4 mg (via one step at 2 mg), 9 mg (via steps at 2 mg, 4 mg and 6 mg) or 12 mg (via steps at 2 mg, 4 mg, 6 mg and 9 mg).”<\/p>\n Run the arithmetic that schedule implies. A participant assigned to 12 mg sat at 2 mg, then 4 mg, then 6 mg, then 9 mg, four weeks at each step, before a first 12 mg injection, which puts the top dose roughly sixteen weeks into an eighty-week trial. A participant assigned to 4 mg arrived there inside a month.<\/p>\n The results, from the New England Journal of Medicine report of September 29, 2026<\/a>, give the mean change in body weight at 80 weeks as minus 17.6% at 4 mg, minus 23.7% at 9 mg and minus 25.0% at 12 mg, against minus 3.9% for placebo, counting all participants randomized. Lilly’s alternative counting rule, which follows participants who stayed on treatment, reports minus 19.0%, or 47.2 lb, at 4 mg, minus 25.9% at 9 mg and minus 28.3%, or 70.3 lb, at 12 mg.<\/p>\n The cost of the top dose sits in the same release. Discontinuation because of an adverse event ran 4.1% at 4 mg and 11.3% at 12 mg, against 4.9% for placebo. Nausea ran 28.6% at 4 mg and 42.4% at 12 mg, against 14.8% for placebo. Lilly calls the 4 mg arm, reached with one escalation step, a patient-centric option on tolerability grounds, and its own numbers say why.<\/p>\n The earlier trial holds the cleanest evidence that a dosing schedule is a design decision rather than a copy-paste. NCT04881760<\/a> randomized 338 adults to 1 mg, 4 mg, 8 mg or 12 mg weekly, or placebo, for 48 weeks. Two of those arms ran to the same destination by different routes: the 4 mg target starting at 2 mg and starting at 4 mg, and the 8 mg target starting at 2 mg and starting at 4 mg.<\/p>\n The published results tables split those arms, which is where the detail lives. At week 24, the 8 mg arm that opened at 4 mg lost 18.26% of body weight. The 12 mg arm, still climbing toward its target from a 2 mg start, lost 17.39%. A lower target, reached faster, beat a higher target, reached slower.<\/p>\n By week 48 the order corrected itself: 24.22% at 12 mg, 23.88% for the fast-ramp 8 mg group, 21.72% for the slow-ramp 8 mg group, 17.83% and 16.32% for the two 4 mg groups, and 2.11% for placebo. The phase 2 report in the New England Journal of Medicine<\/a> compresses the same trial to minus 24.2% at 12 mg and minus 22.8% across the combined 8 mg arms. The height of the target sets the finish line, and the ramp decides how far you travel by week 24 and how punishing the first months are.<\/p>\n The adverse-event tables settle it with two pairs of numbers that no chart online carries, because a chart lists only the destination.<\/p>\n At the 4 mg target, 6 of 33 participants, or 18%, reported nausea in the arm that started at 2 mg, against 12 of 33, or 36%, in the arm that opened at 4 mg. At the 8 mg target, 6 of 35, or 17%, reported nausea with a 2 mg start, against 21 of 35, or 60%, with a 4 mg start. Vomiting ran 2 of 35 against 9 of 35 at that same 8 mg target.<\/p>\n The phase 2 publication states the finding in one clause: those events “were partially mitigated with a lower starting dose (2 mg vs. 4 mg).”<\/p>\n That is the trap in the chart. Reading “8 mg weekly” off a table tells you where participants finished. It does not tell you that the participants who felt worst arrived at 8 mg from 4 mg in a single hop, which is 60% nausea, against 17% among the participants who took the stairs.<\/p>\n The same tables carry a signal unique to this molecule. The phase 2 authors describe the gastrointestinal events as dose-related and mostly mild to moderate, and note that heart rate rose with dose, peaked at week 24 and declined afterward. Allodynia, an unpleasant skin sensitivity, appeared in 4 of 62 participants at the 12 mg target and in none of the placebo or lower-dose arms.<\/p>\n A vial that carries a milligram figure and no escalation schedule is a label with a number on it, and the FDA has been explicit about how sellers dress those up. The agency reports that it has warned companies marketing unapproved drugs containing retatrutide, semaglutide, tirzepatide, survodutide or mazdutide while falsely labelling the products “for research purposes” or “not for human consumption.” Strip that phrase off the listing and what remains is a schedule somebody invented, sold beside a syringe.<\/p>\n Two limits belong on the record, and the FDA states both. The agency cannot always determine whether a reported adverse event came from a product or from other factors, and federal law does not require state-licensed pharmacies that are not outsourcing facilities to submit adverse events at all, so the published counts understate what happens.<\/p>\n For the side-effect numbers that belong to this molecule, our retatrutide side effects breakdown<\/a> collects the primary documents.<\/p>\n There is no approved retatrutide dosage, because retatrutide is not an approved drug. The doses studied in trials ran from 1 mg to 12 mg once weekly. The FDA states that retatrutide cannot be used in compounding under federal law.<\/p>\n The phase 2 trial tested 1 mg, 4 mg, 8 mg and 12 mg once weekly for 48 weeks, some arms starting at 2 mg and some at 4 mg. The phase 3 TRIUMPH-1 trial tested 4 mg, 9 mg and 12 mg once weekly for 80 weeks, with placebo in both.<\/p>\n The trial protocol is public and it is not a prescription. In TRIUMPH-1, participants began at 2 mg once weekly and increased one step every four weeks toward a target of 4 mg, 9 mg or 12 mg. Treatment ran 80 weeks.<\/p>\n On the published TRIUMPH-1 schedule, one step per four weeks, the 4 mg target arrives in about a month and the 12 mg target arrives around sixteen weeks into treatment. That is a protocol detail, not medical advice.<\/p>\n Because the 12 mg arm was still climbing. In the phase 2 results, the 8 mg arm that opened at 4 mg lost 18.26% of body weight by week 24, while the 12 mg arm, ramping from 2 mg, lost 17.39%. By week 48 the 12 mg arm led at 24.22%.<\/p>\n The trial data answers this directly. At the same 8 mg target, nausea hit 60% of participants who started at 4 mg, against 17% of those who started at 2 mg. The phase 2 authors describe a lower starting dose as partially mitigating the gastrointestinal events.<\/p>\n Two disclosures belong on the record. These figures describe an investigational, unapproved drug studied in trials sponsored by its manufacturer, and the compounded products sold under the same name are not the drug those trials studied. Nothing here is a dosing instruction or a substitute for a prescriber who can see your history.<\/p>\n Sources: FDA, concerns with unapproved GLP-1 drugs used for weight loss<\/a>, ClinicalTrials.gov, phase 2 trial NCT04881760<\/a>, ClinicalTrials.gov, TRIUMPH-1 NCT05929066<\/a>, Jastreboff et al., NEJM, 2023<\/a>, Jastreboff et al., NEJM, September 29, 2026<\/a>, Eli Lilly, TRIUMPH-1 topline, May 21, 2026<\/a>.<\/p>\nTRIUMPH-1 – the retatrutide dosing schedule started at 2 mg<\/h2>\n
The 8 mg arm that beat 12 mg – the climb carries the result<\/h2>\n
Nausea – the same target dose produced 18% and 60%<\/h2>\n
The 10 mg vial – a milligram number is not a dosing schedule<\/h2>\n
What to ask instead of a retatrutide dosage chart<\/h2>\n
\n
Frequently asked questions<\/h2>\n
What is the retatrutide dosage?<\/h3>\n
What doses of retatrutide were used in the trials?<\/h3>\n
Is there a retatrutide dosing schedule I can follow?<\/h3>\n
How long does it take to reach the full retatrutide dose?<\/h3>\n
Why did the 8 mg dose beat the 12 mg dose at week 24?<\/h3>\n
What happens if the starting dose is too high?<\/h3>\n